/ Print /

PHARMACY BEST PRACTICES

Are oncology pathways effective? AMCP presenters weigh inFaced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working?
Study: Use of short-acting opioids decrease, long-acting opioids increaseExecutives need to increase awareness in the category and ensure prescribers are aware of CDC guidelines for opioid prescribing and the prescription drug monitoring programs.
Drug pipeline developments: Alopecia areata and atopic dermatitisPromising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.
Nearly half of BCBS members discontinue this RA drug after 1 yearAnalysis from Prime shows that improvements in persistency, adherence is key in RA treatments.
Biosimilars and interchangeable biologics: News to watchBiosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.
Health execs must brace for autoimmune drug changesA comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.
Five specialty pharmaceutical trends to watchApprovals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.
Biomarkers: Top challenges and opportunities in managed careBiomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.
Four developments helping address the opioid epidemicAs the opioid epidemic continues across the U.S., new treatment programs and guidelines could help reverse the trend.
Top risk factors for opioid use disorder, overdoseIn 2014, nearly 2 million Americans met the diagnostic criteria for a past-year prescription opioid use disorder, and at least 14,000 people died from a prescription opioid overdose. Read about the top drivers and risk factors.